Liver Gene Transfer of Interkeukin-15 Constructs That Become Part of Circulating High Density Lipoproteins for Immunotherapy

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Ochoa, Maria C ^a   Fioravanti, Jessica ^a   Duitman, Erwin H ^b   Medina Echeverz, Jose ^a   Palazon, Asis ^a   Arina, Ainhoa ^c   Dubrot, Juan ^a   Alfaro, Carlos ^a   Morales Kastresana, Aizea ^a   Murillo, Oihana ^d   Hervas Stubbs, Sandra ^a   Prieto, Jesus ^a   Berraondo, Pedro ^a   Melero, Ignacio ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b RESEARCH CENTER BORSTEL   (Germany)

^c UNIVERSITY OF CHICAGO   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; APOLIPOPROTEIN A1 INTERLEUKIN 15 RECEPTOR ALPHA FUSION PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; COLON CARCINOMA; COMPLEX FORMATION; CONTROLLED STUDY; DILUTION; DRUG CYTOTOXICITY; DRUG HALF LIFE; GENE CONSTRUCT; HUMAN; LIVER METASTASIS; LYMPHOCYTE PROLIFERATION; MEMORY T LYMPHOCYTE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PHENOTYPE; PROTEIN DOMAIN;

ANIMALS; APOLIPOPROTEIN A-I; BLOTTING, WESTERN; CD8-POSITIVE T-LYMPHOCYTES; CELL COUNT; CELL LINE, TUMOR; CELL PROLIFERATION; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; HUMANS; IMMUNOLOGIC MEMORY; IMMUNOTHERAPY; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-15; INTERLEUKIN-15 RECEPTOR ALPHA SUBUNIT; KILLER CELLS, NATURAL; LIPOPROTEINS, HDL; LIVER; MICE; MICE, INBRED C57BL; NEOPLASM METASTASIS; PHENOTYPE; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT PROTEINS; SPLEEN;

MUS;

EID: 84871353442     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0052370     Document Type: Article

References (50)

1. Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, et al. (2009) The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 15: 5323-5337.
2. Waldmann TA, (2006) The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol 6: 595-601.
3. Oh S, Perera LP, Terabe M, Ni L, Waldmann TA, et al. (2008) IL-15 as a mediator of CD4+ help for CD8+ T cell longevity and avoidance of TRAIL-mediated apoptosis. Proc Natl Acad Sci U S A 105: 5201-5206.
4. Goldrath AW, Sivakumar PV, Glaccum M, Kennedy MK, Bevan MJ, et al. (2002) Cytokine requirements for acute and Basal homeostatic proliferation of naive and memory CD8+ T cells. J Exp Med 195: 1515-1522.
5. Fehniger TA, Suzuki K, Ponnappan A, VanDeusen JB, Cooper MA, et al. (2001) Fatal leukemia in interleukin 15 transgenic mice follows early expansions in natural killer and memory phenotype CD8+ T cells. J Exp Med 193: 219-231.
6. Carson WE, Giri JG, Lindemann MJ, Linett ML, Ahdieh M, et al. (1994) Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J Exp Med 180: 1395-1403.
7. Waldmann TA, Tagaya Y, (1999) The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens. Annu Rev Immunol 17: 19-49.
8. Huntington ND, Legrand N, Alves NL, Jaron B, Weijer K, et al. (2009) IL-15 trans-presentation promotes human NK cell development and differentiation in vivo. J Exp Med 206: 25-34.
9. Kobayashi H, Dubois S, Sato N, Sabzevari H, Sakai Y, et al. (2005) Role of trans-cellular IL-15 presentation in the activation of NK cell-mediated killing, which leads to enhanced tumor immunosurveillance. Blood 105: 721-727.
10. Mignot G, Ullrich E, Bonmort M, Menard C, Apetoh L, et al. (2008) The critical role of IL-15 in the antitumor effects mediated by the combination therapy imatinib and IL-2. J Immunol 180: 6477-6483.
11. Dubois S, Mariner J, Waldmann TA, Tagaya Y, (2002) IL-15Ralpha recycles and presents IL-15 In trans to neighboring cells. Immunity 17: 537-547.
12. Sandau MM, Schluns KS, Lefrancois L, Jameson SC, (2004) Cutting edge: transpresentation of IL-15 by bone marrow-derived cells necessitates expression of IL-15 and IL-15R alpha by the same cells. J Immunol 173: 6537-6541.
13. Lorenzen I, Dingley AJ, Jacques Y, Grotzinger J, (2006) The structure of the interleukin-15 alpha receptor and its implications for ligand binding. J Biol Chem 281: 6642-6647.
14. Wei X, Orchardson M, Gracie JA, Leung BP, Gao B, et al. (2001) The Sushi domain of soluble IL-15 receptor alpha is essential for binding IL-15 and inhibiting inflammatory and allogenic responses in vitro and in vivo. J Immunol 167: 277-282.
15. Duitman EH, Orinska Z, Bulanova E, Paus R, Bulfone-Paus S, (2008) How a cytokine is chaperoned through the secretory pathway by complexing with its own receptor: lessons from interleukin-15 (IL-15)/IL-15 receptor alpha. Molecular and cellular biology 28: 4851-4861.
16. Croce M, Meazza R, Orengo AM, Radic L, De Giovanni B, et al. (2005) Sequential immunogene therapy with interleukin-12- and interleukin-15-engineered neuroblastoma cells cures metastatic disease in syngeneic mice. Clin Cancer Res 11: 735-742.
17. Vera M, Razquin N, Prieto J, Melero I, Fortes P, et al. (2005) Intratumoral injection of dendritic cells transduced by an SV40-based vector expressing interleukin-15 induces curative immunity mediated by CD8+ T lymphocytes and NK cells. Mol Ther 12: 950-959.
18. Chang CM, Lo CH, Shih YM, Chen Y, Wu PY, et al. (2010) Treatment of hepatocellular carcinoma with adeno-associated virus encoding interleukin-15 superagonist. Hum Gene Ther 21: 611-621.
19. Klebanoff CA, Finkelstein SE, Surman DR, Lichtman MK, Gattinoni L, et al. (2004) IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc Natl Acad Sci U S A 101: 1969-1974.
20. Oh S, Berzofsky JA, Burke DS, Waldmann TA, Perera LP, (2003) Coadministration of HIV vaccine vectors with vaccinia viruses expressing IL-15 but not IL-2 induces long-lasting cellular immunity. Proc Natl Acad Sci U S A 100: 3392-3397.
21. Steel JC, Ramlogan CA, Yu P, Sakai Y, Forni G, et al. (2010) Interleukin-15 and its receptor augment dendritic cell vaccination against the neu oncogene through the induction of antibodies partially independent of CD4 help. Cancer Res 70: 1072-1081.
22. Dubois S, Patel HJ, Zhang M, Waldmann TA, Muller JR, (2008) Preassociation of IL-15 with IL-15R alpha-IgG1-Fc enhances its activity on proliferation of NK and CD8+/CD44high T cells and its antitumor action. J Immunol 180: 2099-2106.
23. Rubinstein MP, Kovar M, Purton JF, Cho JH, Boyman O, et al. (2006) Converting IL-15 to a superagonist by binding to soluble IL-15R{alpha}. Proc Natl Acad Sci U S A 103: 9166-9171.
24. Stoklasek TA, Schluns KS, Lefrancois L, (2006) Combined IL-15/IL-15Ralpha immunotherapy maximizes IL-15 activity in vivo. J Immunol 177: 6072-6080.
25. Berger C, Berger M, Hackman RC, Gough M, Elliott C, et al. (2009) Safety and immunologic effects of IL-15 administration in nonhuman primates. Blood 114: 2417-2426.
26. Lugli E, Goldman CK, Perera LP, Smedley J, Pung R, et al. (2010) Transient and persistent effects of IL-15 on lymphocyte homeostasis in nonhuman primates. Blood 116: 3238-3248.
27. Munger W, DeJoy SQ, Jeyaseelan R Sr, Torley LW, Grabstein KH, et al. (1995) Studies evaluating the antitumor activity and toxicity of interleukin-15, a new T cell growth factor: comparison with interleukin-2. Cell Immunol 165: 289-293.
28. Kennedy MK, Glaccum M, Brown SN, Butz EA, Viney JL, et al. (2000) Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J Exp Med 191: 771-780.
29. Lodolce JP, Boone DL, Chai S, Swain RE, Dassopoulos T, et al. (1998) IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation. Immunity 9: 669-676.
30. Sadlack B, Merz H, Schorle H, Schimpl A, Feller AC, et al. (1993) Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 75: 253-261.
31. Francis GA, (2010) The complexity of HDL. Biochim Biophys Acta 1801: 1286-1293.
32. Lund-Katz S, Phillips MC, (2010) High density lipoprotein structure-function and role in reverse cholesterol transport. Subcell Biochem 51: 183-227.
33. Fioravanti J, Gonzalez I, Medina-Echeverz J, Larrea E, Ardaiz N, et al. (2011) Anchoring interferon alpha to apolipoprotein A-I reduces hematological toxicity while enhancing immunostimulatory properties. Hepatology.
34. Zabala M, Lasarte JJ, Perret C, Sola J, Berraondo P, et al. (2007) Induction of immunosuppressive molecules and regulatory T cells counteracts the antitumor effect of interleukin-12-based gene therapy in a transgenic mouse model of liver cancer. J Hepatol 47: 807-815.
35. Arina A, Murillo O, Dubrot J, Azpilikueta A, Gabari I, et al. (2008) Interleukin-15 liver gene transfer increases the number and function of IKDCs and NK cells. Gene Ther 15: 473-483.
36. Melero I, Duarte M, Ruiz J, Sangro B, Galofre J, et al. (1999) Intratumoral injection of bone-marrow derived dendritic cells engineered to produce interleukin-12 induces complete regression of established murine transplantable colon adenocarcinomas. Gene Ther 6: 1779-1784.
37. Soman G, Yang X, Jiang H, Giardina S, Vyas V, et al. (2009) MTS dye based colorimetric CTLL-2 cell proliferation assay for product release and stability monitoring of interleukin-15: assay qualification, standardization and statistical analysis. J Immunol Methods 348: 83-94.
38. Meazza R, Lollini PL, Nanni P, De Giovanni C, Gaggero A, et al. (2000) Gene transfer of a secretable form of IL-15 in murine adenocarcinoma cells: effects on tumorigenicity, metastatic potential and immune response. Int J Cancer 87: 574-581.
39. Fioravanti J, Gonzalez I, Medina-Echeverz J, Larrea E, Ardaiz N, et al. (2011) Anchoring interferon alpha to apolipoprotein A-I reduces hematological toxicity while enhancing immunostimulatory properties. Hepatology 53: 1864-1873.
40. He Y, Pimenov AA, Nayak JV, Plowey J, Falo LD Jr, et al. (2000) Intravenous injection of naked DNA encoding secreted flt3 ligand dramatically increases the number of dendritic cells and natural killer cells in vivo. Hum Gene Ther 11: 547-554.
41. Rodriguez-Sureda V, Julve J, Llobera M, Peinado-Onsurbe J, (2002) Ultracentrifugation micromethod for preparation of small experimental animal lipoproteins. Anal Biochem 303: 73-77.
42. Mortier E, Quemener A, Vusio P, Lorenzen I, Boublik Y, et al. (2006) Soluble interleukin-15 receptor alpha (IL-15R alpha)-sushi as a selective and potent agonist of IL-15 action through IL-15R beta/gamma. Hyperagonist IL-15×IL-15R alpha fusion proteins. The Journal of biological chemistry 281: 1612-1619.
43. Su F, Kozak KR, Imaizumi S, Gao F, Amneus MW, et al. (2010) Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides inhibit tumor development in a mouse model of ovarian cancer. Proc Natl Acad Sci U S A 107: 19997-20002.
44. Martinez Forero I, Okada H, Topalian SL, Gajewski TF, Korman AJ, et al. (2012) Workshop on immunotherapy combinations. Society for Immunotherapy of Cancer annual meeting Bethesda, November 3, 2011. J Transl Med 10: 108.
45. Suda T, Liu D, (2007) Hydrodynamic gene delivery: its principles and applications. Mol Ther 15: 2063-2069.
46. Bonamassa B, Hai L, Liu D (2010) Hydrodynamic Gene Delivery and Its Applications in Pharmaceutical Research. Pharm Res.
47. Mortier E, Quemener A, Vusio P, Lorenzen I, Boublik Y, et al. (2006) Soluble interleukin-15 receptor alpha (IL-15R alpha)-sushi as a selective and potent agonist of IL-15 action through IL-15R beta/gamma. Hyperagonist IL-15×IL-15R alpha fusion proteins. J Biol Chem 281: 1612-1619.
48. Yu P, Steel JC, Zhang M, Morris JC, Waldmann TA, (2010) Simultaneous blockade of multiple immune system inhibitory checkpoints enhances antitumor activity mediated by interleukin-15 in a murine metastatic colon carcinoma model. Clin Cancer Res 16: 6019-6028.
49. Tirapu I, Arina A, Mazzolini G, Duarte M, Alfaro C, et al. (2004) Improving efficacy of interleukin-12-transfected dendritic cells injected into murine colon cancer with anti-CD137 monoclonal antibodies and alloantigens. International journal of cancer Journal international du cancer 110: 51-60.
50. Dubrot J, Portero A, Orive G, Hernandez RM, Palazon A, et al. (2010) Delivery of immunostimulatory monoclonal antibodies by encapsulated hybridoma cells. Cancer Immunol Immunother 59: 1621-1631.